HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Radiosensitizing effect of a 2-nitroimidazole hydroxamate (KIN-804) to murine tumors].

Abstract
We studied the toxicity, pharmacokinesis and radiosensitizing effect of a newly developed 2-nitroimidazole-1-methylacetohydroxamate (KIN-804) in C3H/He mice bearing SCC-VII tumor. They were compared with misonidazole. LD50/7 of KIN-804 and misonidazole were 3200 and 2000 mg/kg. The concentration of KIN-804 in the brain and sciatic nerve was at a very low level and its clearance from the sciatic nerve was rapid. Enhancement ratios calculated using the growth delay method were 1.50 for KIN-804 and 1.36 for misonidazole respectively when they were administered by intraperitoneal injection with a dose of 100 mg/kg. KIN-804 was considered to be a promising radiosensitizer because it obtained less toxicity and a higher radiosensitizing activity than misonidazole.
AuthorsT Tada, T Nakajima, Y Onoyama, H Nagasawa, H Hori, S Inayama
JournalNihon Igaku Hò„shasen Gakkai zasshi. Nippon acta radiologica (Nihon Igaku Hoshasen Gakkai Zasshi) Vol. 52 Issue 5 Pg. 688-90 (May 25 1992) ISSN: 0048-0428 [Print] JAPAN
PMID1508643 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Hydroxamic Acids
  • Nitroimidazoles
  • Radiation-Sensitizing Agents
  • 2-nitroimidazole-1-methylacetohydroxamate
Topics
  • Animals
  • Hydroxamic Acids (pharmacokinetics, pharmacology, toxicity)
  • Lethal Dose 50
  • Male
  • Mice
  • Mice, Inbred C3H
  • Neoplasms, Experimental (metabolism, pathology, radiotherapy)
  • Nitroimidazoles (pharmacokinetics, pharmacology, toxicity)
  • Radiation-Sensitizing Agents (pharmacokinetics, pharmacology, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: